Cited 0 times in Scipus Cited Count

Fecal Calprotectin at Postinduction Is Capable of Predicting Persistent Remission and Endoscopic Healing after 1 Year of Treatment with Infliximab in Pediatric Patients with Crohn’s Disease

DC Field Value Language
dc.contributor.authorLee, YM-
dc.contributor.authorKim, ES-
dc.contributor.authorChoi, S-
dc.contributor.authorJang, HJ-
dc.contributor.authorKim, YB-
dc.contributor.authorChoi, SY-
dc.contributor.authorChoe, BH-
dc.contributor.authorKang, B-
dc.date.accessioned2024-07-05T01:28:07Z-
dc.date.available2024-07-05T01:28:07Z-
dc.date.issued2024-
dc.identifier.issn1976-2283-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/32617-
dc.description.abstractBackground/Aims: The recent update on Selecting Therapeutic Targets in Inflammatory Bowel Disease initiative has added a decrease in fecal calprotectin (FC) to an acceptable range as an intermediate target for Crohn’s disease (CD). We aimed to investigate whether postinduction FC could predict future persistent remission (PR) and endoscopic healing (EH) after 1 year of treatment with infliximab (IFX) in pediatric patients with CD. Methods: This multicenter retrospective observational study included pediatric patients with CD who were followed up for at least 1 year after starting IFX. The association of postinduction FC with PR and EH was investigated. Results: A total of 132 patients were included in this study. PR and EH were observed in 71.2% (94/132) and 73.9% (82/111) of the patients, respectively. In multivariate logistic regression analysis, only the postinduction FC level was associated with PR (odds ratio [OR], 0.26; 95% confidence interval [CI], 0.08 to 0.66; p=0.009). The FC levels at initiation of IFX and postinduction were significantly associated with EH (OR, 0.73; 95% CI, 0.53 to 0.99; p=0.044 and OR, 0.20; 95% CI, 0.06 to 0.49; p=0.002, respectively). According to the receiver operating characteristic curve analysis, the optimal cutoff level for postinduction FC associated with PR was 122 mg/kg, and that associated with EH was 377 mg/kg. Conclusions: Postinduction FC was associated with PR and EH after 1 year of treatment with IFX in pediatric patients with CD. Our findings emphasize the importance of FC as an intermediate target in the treat-to-target era.-
dc.language.isoen-
dc.subject.MESHAdolescent-
dc.subject.MESHBiomarkers-
dc.subject.MESHChild-
dc.subject.MESHCrohn Disease-
dc.subject.MESHFeces-
dc.subject.MESHFemale-
dc.subject.MESHGastrointestinal Agents-
dc.subject.MESHHumans-
dc.subject.MESHInfliximab-
dc.subject.MESHLeukocyte L1 Antigen Complex-
dc.subject.MESHLogistic Models-
dc.subject.MESHMale-
dc.subject.MESHPredictive Value of Tests-
dc.subject.MESHRemission Induction-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHTreatment Outcome-
dc.titleFecal Calprotectin at Postinduction Is Capable of Predicting Persistent Remission and Endoscopic Healing after 1 Year of Treatment with Infliximab in Pediatric Patients with Crohn’s Disease-
dc.typeArticle-
dc.identifier.pmid38013474-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11096907-
dc.subject.keywordCalprotectin-
dc.subject.keywordCrohn disease-
dc.subject.keywordInfliximab-
dc.subject.keywordPrognosis-
dc.contributor.affiliatedAuthorKim, YB-
dc.type.localJournal Papers-
dc.identifier.doi10.5009/gnl230022-
dc.citation.titleGut and liver-
dc.citation.volume18-
dc.citation.number3-
dc.citation.date2024-
dc.citation.startPage498-
dc.citation.endPage508-
dc.identifier.bibliographicCitationGut and liver, 18(3). : 498-508, 2024-
dc.identifier.eissn2005-1212-
dc.relation.journalidJ019762283-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Pediatrics & Adolescent Medicine
Files in This Item:
38013474.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse